A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 32796842.
- Also identified by DOI 10.1038/s41467-020-17972-1 and PMC identifier 7427994.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The unprecedented coronavirus disease 2019 (COVID-19) epidemic has created a worldwide public health emergency, and there is an urgent need to develop an effective vaccine to control this severe infectious disease. Here, we find that a single vaccination with a replication-defective human type 5 adenovirus encoding the SARS-CoV-2 spike protein (Ad5-nCoV) protect mice completely against mouse-adapted SARS-CoV-2 infection in the upper and lower respiratory tracts. Additionally, a single vaccination with Ad5-nCoV protects ferrets from wild-type SARS-CoV-2 infection in the upper respiratory tract. This study suggests that the mucosal vaccination may provide a desirable protective efficacy and this delivery mode is worth further investigation in human clinical trials.
Medical subject headings
- Betacoronavirus
- Coronavirus Infections
- Pandemics
- Pneumonia, Viral
- Viral Vaccines